Presbyopia Drops, a Promising Solution

Careful patient selection, thorough education, and setting realistic expectations by ophthalmologists and staff help patients maximize their benefits.

Irene Zhou, BS, MS3Ariana Rose Maleki, BSDagny Zhu, MD

Ophthalmic Professional April 1, 2025 Vol 14, Issue April 2025 Page(s): 17-18

Clinical Report: Presbyopia Drops, a Promising Solution

Overview

Presbyopia drops, specifically Vuity and Qlosi, offer a non-invasive treatment option for patients over 40, improving near vision while preserving distance vision. Careful patient selection and education are crucial for maximizing the benefits of these drops.

Background

Presbyopia significantly affects near vision and quality of life for individuals over 40. Traditional management options include corrective lenses and surgical interventions, which may not be suitable for all patients. The introduction of presbyopia drops represents a promising alternative, providing a non-invasive solution for those seeking relief from presbyopia.

Data Highlights

Clinical trials have demonstrated significant improvements in near vision with presbyopia drops, with Vuity showing 3-line or greater improvements in near visual acuity. Qlosi has also shown similar efficacy without significant loss of distance vision.

Key Findings

Vuity and Qlosi are the only FDA-approved pharmacologic treatments for presbyopia.
Vuity is effective for patients aged 40 to 50 with early to moderate presbyopia, providing functional near vision.
Qlosi can be used twice daily, extending the duration of effect up to 8 hours.
Careful patient selection is essential for optimal outcomes, particularly for those with retinal conditions.
Common side effects include temporary brow ache and headaches, which may occur during the initial adjustment period.

Clinical Implications

Ophthalmologists should prioritize careful patient selection and thorough education regarding the use of presbyopia drops. Emphasizing the temporary nature of the treatment and the importance of adherence to the eyedrop regimen can enhance patient outcomes.

Conclusion

Presbyopia drops present a valuable non-invasive option for managing presbyopia, with careful patient selection and education being key to achieving successful outcomes.

PentaVision

Ophthalmic Professional